Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

Acute Bacterial Rhinosinusitis, Update

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Full Title: Update on Acute Bacterial Rhinosinusitis

June 2005

View or download Summary/Report


Structured Abstract

Context: Our last report on the treatment of acute bacterial sinusitis was published in 1999. Since then, many more trials were published comparing different antibiotics not found in the previous report. In addition, universal pneumococcal vaccination was introduced in the pediatric population. It is of interest to examine the effects of these new developments on the treatment of acute bacterial rhinosinusitis.

Objectives: To perform a systematic review of the literature published since 1997 on comparisons of antibiotics in the treatment of acute bacterial rhinosinusitis, to summarize the adverse events and note any reported impact of pneumococcal vaccine on the treatment of acute bacterial rhinosinusitis.

Data Sources: We searched the MEDLINE® database and bibliographies of selected reviews. Additional studies were provided by technical experts.

Study Selection: English-language, comparative trials of antibiotics for the treatment of acute bacterial rhinosinusitis in both adult and pediatric populations were included. Studies of sinusitis with complications or that included both subjects with sinusitis and subjects with other respiratory tract infections were excluded.

Data Extraction: We extracted information about the study design, demographics, eligibility criteria, antibiotic dosing regimens, outcome measures, including dropouts, and adverse events. Based on these data, studies were graded for quality.

Data Synthesis: Thirty-nine randomized controlled trials from 1997 to 2004 met the inclusion criteria for this report. With the exception of 5 studies that did not provide the information, all studies were either funded by pharmaceutical companies or had authors associated with the pharmaceutical industry. Only one study exclusively evaluated pediatric population. The trials evaluated penicillins, cephalosporins, macrolides, azalides, ketolides, quinolones, carbapenems and tetracyclines. In 5 placebo-controlled trials, antibiotics were more effective than placebo, reducing the risk of clinical failure by about 25-30 percent 7 to 14 days after treatment initiation. Compared to amoxicillin/clavulanate, treatment with cephalosporins result in about 3.5 more clinical failures per 100 patients at 10-25 days after treatment initiation. There was no consistent difference observed when comparing amoxicillin-clavulanate, cephalosporins and quinolones to the group encompassing macrolides, azalides and ketolide.

Eight studies that evaluated different treatment durations generally found no differences in efficacy outcomes between the shorter and longer duration therapies.

Thirty-four of the comparative trials and five additional non-comparative studies reported adverse events. Descriptions of adverse events were diverse among studies. It was not possible to make meaningful comparisons of adverse event rates across different antibiotic classes given the large variation in the adverse event rates within the same antibiotic class. Overall, the most common adverse events involved the gastrointestinal and the nervous system (such as headache). We did not identify any article in our literature search that directly addressed the impact of pneumococcal vaccine on the treatment of acute bacterial rhinosinusitis.

Conclusions: About two-thirds of the patients with acute rhinosinusitis receiving placebos recovered without antibiotics. Antibiotics are superior to placebo in the treatment of rhinosinusitis. Amoxicillin/clavulanate is more effective than the cephalosporin class of antibiotics in the treatment of sinusitis only in the short-term followup, with an absolute risk difference of about 3.5 percent.

There are only a few studies that specifically examined the effect of different treatment duration on outcome efficacy; they generally found no difference between shorter and longer duration of treatment. It is not possible to compare the rates of adverse events across different antibiotic classes. Severe adverse events in general are uncommon; they occurred in up to about 3.5 percent of patients in all classes of antibiotics.

As of September 2004, there have not been any published studies examining the effect of the pneumococcal vaccine on the treatment of acute sinusitis.

A minority of studies were placebo controlled. In addition, from a health care cost standpoint, there were very few comparative studies between newer antibiotics and older inexpensive ones (like amoxicillin and trimethoprim/sulfamethoxazole).


Download Report

Update on Acute Bacterial Rhinosinusitis

Evidence-based Practice Center: Tufts-New England Medical Center
Topic Nominators: American Academy of Otolaryngology-Head and Neck Surgery, American Academy of Family Physicians, American Academy of Pediatrics, American College of Physicians

Current as of June 2005

 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care